Your browser doesn't support javascript.
loading
Safety and effectiveness of biphasic insulin aspart 30 in people with type 2 diabetes switching from basal-bolus insulin regimens in the A1chieve study.
Dieuzeide, Guillermo; Chuang, Lee-Ming; Almaghamsi, Abdulrahman; Zilov, Alexey; Chen, Jian-Wen; Lavalle-González, Fernando J.
Afiliación
  • Dieuzeide G; Centro de Atención Integral en Diabetes, Endocrinología y Metabolismo, Chacabuco, Province of Buenos Aires, Argentina.
  • Chuang LM; Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
  • Almaghamsi A; Medicine Department, King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia.
  • Zilov A; Department of Endocrinology, First Moscow State Medical University, Moscow, Russia.
  • Chen JW; Novo Nordisk Region International Operations A/S, Zurich, Switzerland. Electronic address: jwch@novonordisk.com.
  • Lavalle-González FJ; Endocrine Service at the University Hospital "Dr José E González" School of Medicine UANL, Monterrey, Mexico.
Prim Care Diabetes ; 8(2): 111-7, 2014 Jul.
Article en En | MEDLINE | ID: mdl-23953707
AIMS: Biphasic insulin aspart 30 allows fewer daily injections versus basal-bolus insulin regimens, which may improve adherence and treatment outcome. This sub-analysis of the observational A1chieve study assessed clinical safety and effectiveness of biphasic insulin aspart 30 in people with type 2 diabetes previously receiving basal-bolus insulin regimens. METHODS: A1chieve was an international, open-label, 24-week study in people with type 2 diabetes starting/switching to biphasic insulin aspart 30, insulin detemir or insulin aspart. This sub-analysis assessed patients switching from insulin glargine- or neutral protamine Hagedorn insulin-based basal-bolus insulin regimens to biphasic insulin aspart 30. RESULTS: 1024 patients were included. At 24 weeks, glycated haemoglobin and fasting plasma glucose were significantly reduced from baseline in both cohorts (all p<0.001). The proportion reporting any hypoglycaemia, major hypoglycaemia or nocturnal hypoglycaemia was significantly reduced after 24 weeks (all p<0.05). No serious adverse drug reactions were reported. Both cohorts had significantly improved health-related quality of life (HRQoL; p<0.001). CONCLUSIONS: 24 weeks after switching from basal-bolus insulin regimens to biphasic insulin aspart 30, glycaemic control and HRQoL were significantly improved, and hypoglycaemia was significantly reduced. This suggests that people with type 2 diabetes inadequately controlled on basal-bolus insulin regimens can consider biphasic insulin aspart 30.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Hemoglobina Glucada / Diabetes Mellitus Tipo 2 / Sustitución de Medicamentos / Insulinas Bifásicas / Insulina Aspart / Hipoglucemiantes / Insulina Isófana Tipo de estudio: Clinical_trials / Diagnostic_studies / Observational_studies Aspecto: Patient_preference Límite: Adult / Aged / Female / Humans / Male / Middle aged País/Región como asunto: Africa / Asia / Europa Idioma: En Revista: Prim Care Diabetes Asunto de la revista: ENDOCRINOLOGIA Año: 2014 Tipo del documento: Article País de afiliación: Argentina Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Hemoglobina Glucada / Diabetes Mellitus Tipo 2 / Sustitución de Medicamentos / Insulinas Bifásicas / Insulina Aspart / Hipoglucemiantes / Insulina Isófana Tipo de estudio: Clinical_trials / Diagnostic_studies / Observational_studies Aspecto: Patient_preference Límite: Adult / Aged / Female / Humans / Male / Middle aged País/Región como asunto: Africa / Asia / Europa Idioma: En Revista: Prim Care Diabetes Asunto de la revista: ENDOCRINOLOGIA Año: 2014 Tipo del documento: Article País de afiliación: Argentina Pais de publicación: Reino Unido